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Background: The success of using glycolytic inhibitors for cancer treatment relies on better understanding the
roles of each frequently deregulated glycolytic genes in cancer. This report analyzed the involvement of a key
glycolytic enzyme, alpha-enolase (ENO1), in tumor progression and prognosis of human glioma.
Methods: ENO1 expression levels were examined in glioma tissues and normal brain (NB) tissues. The molecular
mechanisms of ENO1 expression and its effects on cell growth, migration and invasion were also explored by
3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, Transwell chamber assay, Boyden chamber
assay, Western blot and in vivo tumorigenesis in nude mice.
Results: ENO1 mRNA and protein levels were upregulated in glioma tissues compared to NB. In addition, increased
ENO1 was associated disease progression in glioma samples. Knocking down ENO1 expression not only significantly
decreased cell proliferation, but also markedly inhibited cell migration and invasion as well as in vivo tumorigenesis.
Mechanistic analyses revealed that Cyclin D1, Cyclin E1, pRb, and NF-κB were downregulated after stable ENO1
knockdown in glioma U251 and U87 cells. Conversely, knockdown of ENO1 resulted in restoration of E-cadherin
expression and suppression of mesenchymal cell markers, such as Vimentin, Snail, N-Cadherin, β-Catenin and Slug.
Furthermore, ENO1 suppression inactivated PI3K/Akt pathway regulating the cell growth and epithelial-mesenchymal
transition (EMT) progression.
Conclusion: Overexpression of ENO1 is associated with glioma progression. Knockdown of ENO1 expression led to
suppressed cell growth, migration and invasion progression by inactivating the PI3K/Akt pathway in glioma cells.
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Malignant gliomas account for the vast majority of adult
malignant brain tumors that are graded according to the
WHO classification system, which has implications
for prognosis and management [1]. The current standard
therapy includes maximal safe resection followed by radio-
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reproduction in any medium, provided the orof patients succumb to the disease within 2 years of diag-
nosis [3].
Glioblastoma, like most cancers, possesses a unique
bioenergetic state of aerobic glycolysis known as the
Warburg effect [4]. Malignant glioma cells thrive despite
an irregular blood supply and frequently in a hypoxic
microenvironment [5]. Compensatory mechanisms, in-
cluding glucose uptake and glycolytic activity, are in-
creased in these tumors [6]. Recent studies indicated that
some glycolytic enzymes are complicated, multifaceted
proteins rather than simple components of the glycolytic
pathway [7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ATP-generated conversion of 2-phosphoglycerate to phos-
phoenolpyruvate. In mammals, there are three different
enolase isoforms: alpha-, beta,-and gamma-enolase. Each
are encoded by three distinct genes and expressed in
a tissue and development-specific manner [8,9]. The
alpha-enolase (ENO1) is a key glycolytic enzyme that
plays a functional role in several physiological pro-
cesses depending on its cellular localization [10]. It
mainly localizes in the cytoplasm as a 48 kDa ENO1
enzyme, while an alternatively translated form is pre-
dominantly in the nuclear region. The nuclear form
has been characterized as a 37 kDa c-Myc promoter-
binding protein (MBP-1), and is negative transcription
factor [11]. In tumor cells, ENO1 is upregulated and
activated by several glucose transporters and glyco-
lytic enzymes that contribute to the Warburg effect [12].
Warburg observed that cancer cells consume more glu-
cose than normal cells and generate ATP by converting
pyruvate to lactic acid, even in the presence of a normal
oxygen supply. Increased ENO1 gene activity and protein
production has been detected in several tumors [13].
ENO1 glycolytic activity is strongly associated with in-
creased ATP citrate lyase expression in gliomas [14], thus
ENO1 may act as a metabolic tumor promoter conferring
a selective growth advantage onto ENO1-overexpressing
tumor cells. The exact mechanisms by which ENO1 ex-
pression is mediated and its function in glioma are not
well understood currently.
In this study, we evaluated the expression of ENO1
in human patient samples. To explore its associated
molecular mechanisms in glioma cells, we examined
the effect of targeted silencing of ENO1 gene on cell pro-
liferation, migration and invasion using shRNA in vitro
and vivo. These studies will be useful in identifying
potential candidates for targeted therapeutic interven-
tion of glioma.
Results
Expression of ENO1 gene in glioma and NB tissues
In order to assess the role of ENO1 in glioma, we per-
formed real-time PCR to measure the expression of
ENO1 mRNA transcripts in 45 freshly collected glioma
tissues and 15 freshly collected NB tissues. Compared
with NB tissues, glioma tissues exhibited higher expres-
sion levels of ENO1 mRNA (P < 0.0001) (Figure 1A).
ENO1 protein (48 kDa) was found to be up-regulated in
10 cases of glioma (WHO IV) compared with 4 NB tis-
sues by Western blot (P < 0.0001) (Figure 1B). We also
measured the expression levels and subcellular localization
of ENO1 protein in 136 archived paraffin-embedded
glioma samples and 15 NB tissues using immunohisto-
chemical staining (Figure 1C). ENO1 protein was highly
expressed in 69.1% (94/136) of glioma samples, while onlyin 20.0% (3/15) of NB samples, a significantly lower fre-
quency (P < 0.001) (Table 1).
Relationship between clinicopathologic characteristics
and ENO1 expression in glioma patients
The relationship between clinicopathologic character-
istics and ENO1 expression levels in individuals with
glioma are summarized in Table 2. We found no sig-
nificant association between ENO1 expression levels
and patients’ age, sex or histologic type in the 136
glioma cases. However, we observed that the expres-
sion level of ENO1 was positively correlated with the
status of pathology classification (WHO I-II vs. WHO
III-IV) (P = 0.000) in glioma patients (Table 2). To de-
termine whether ENO1 is an independent prognostic
factor for glioma, we performed multivariate analysis
of ENO1 expression adjusted for the same parame-
ters. The results indicated that the level of ENO1 ex-
pression was an independent prognostic factor for
glioma (P < 0.001) (Table 3).
Survival analysis
To investigate the prognostic value of ENO1 expression
in glioma, we assessed the association between levels
of tumor ENO1 expression and patients’ survival using
Kaplan-Meier analysis with the log-rank test. In the 136
glioma cases with survival data, we observed that the level
of ENO1 protein expression was significantly correlated
with overall survival. Patients with tumors expressing
low levels of ENO1 expression had better survival than
those with tumors expressing high expression (Figure 2)
(P < 0.001).
Stably downregulated ENO1 expression suppresses cell
proliferation, colony formation and in vivo tumorigenicity
We used a lentiviral shRNA vector to specifically and
stably knock down the expression of ENO1 in U87 and
U251 cell lines that were established from high-grade
tumors. Transcriptional levels of ENO1 were assessed
by RT-PCR, with the most efficient knockdowns from
shENO1-C in U251 cell line and shENO1-A in U87 cell
line compared to the empty vector controls [pLVTHM-
GFP-Control (PLV-Ctr)] (P < 0.01) (Figure 3A). Consistent
results for protein levels were observed by Western blot
(Figure 3B).
Subsequently, we examined the effect of decreased
ENO1 expression on glioma cell growth in vitro. Using an
MTT assay, we found that the growth of shENO1 U251
and U87 cells was significantly slower than the PLV-Ctr
cells from day 1 (P < 0.05) (Figure 4A). Interestingly, simi-
lar results were also observed in siRNA-mediated suppres-
sion of ENO1 in glioma cells. We found that knocking
down endogenous ENO1 expression decreased cell prolif-
eration compared to the negative control (NC) groups
Figure 1 Expression of ENO1 gene in glioma and NB tissues. (A). mRNA expression of ENO1 is decreased in NB tissues compared with
glioma tissues by real-time PCR assay. Data are presented were presented as mean ± SD for three independent experiments (*P < 0.05). (B).
Western blot analysis of ENO1 expression in 10 cases of WHO IV glioma tissue samples compared with 4 NB tissues. The unpaired t-test was used
for this assay (*P < 0.05). (C). ENO1 expression was increased in 136 primary glioma samples compared to 15 normal brain tissues using
immunohistochemical staining. a). Weak staining of ENO1 in NB tissues. b). Strong staining of ENO1 in NB tissues. c and d). Weak staining of
ENO1 in glioma samples. e and f). Strong staining of ENO1 in glioma samples. Original magnification 400 × .
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pressing ENO1 significantly inhibited cell proliferation
compared to PLV-Ctr cells (Figure 4C). To confirm the
growth enhancing effects of ENO1, we performed an
in vivo tumorigenesis study by inoculating shENO1 U251
and U87 cells into nude mice. Mice in the shENO1-U251
and PLV-Ctr groups were sacrificed 18 days after inocula-
tion, with average tumor weights of 0.223 g and 0.713 g,
respectively (P < 0.01). In shENO1-U87 and PLV-CtrTable 1 Protein expression of HDGF between glioma and
NB tissues
Group Cases Protein expression P value
High expression Low expression
Glioma 136 94 42
Normal 15 4 11 0.000groups, the average tumor weights were 0.243 g and
0.677 g, respectively (P < 0.01) (Figure 4D). Immunohisto-
chemistry staining verified normal expression of ENO1 in
the PLV-Ctr–xenografted tumors compared with reduced
or lack of expression in shENO1–xenografted tumors
(Figure 4E). These results suggested a significant inhibi-
tory effect of decreased ENO1 on in vivo tumorigenesis.
Knockdown of ENO1 suppresses glioma cell migration
and invasion in vitro
To examine the effect of ENO1 on cell migration, shRNA-
ENO1 infected U251 and U87 glioma cells were cultured
on Transwell apparatus. After 12 hr incubation, the per-
centage of migrated cells in both shENO1-U251 and
shENO1-U87 glioma cell groups was significantly less than
that in the PLV-Ctr cells (for both P < 0.01) (Figure 5A).
Using a Boyden chamber coated with matrigel, we
Table 2 Correlation between the clinicopathologic
characteristics and expression of HDGF protein in glioma
Characteristics n ENO1 (%) P
High-expression Low-expression
Gender
Male 88 63 (71.6%) 25 (28.4%)
Female 48 31 (64.6%) 17 (35.4%) 0.398
Age
≥50 73 50 (68.5%) 23 (31.5%)
<50 63 44 (69.8%) 19 (30.2%) 0.865
Histologic type
Astrocytic tumors 98 67 (68.4%) 31 (31.6%)
Oligodendrogial
tumors
15 14 (93.3%) 1 (6.7%)
Oligoastrocytic tumors 23 13 (56.5%) 10 (43.5%) 0.053
WHO grade
I + II 41 18 (43.9%) 23 (56.1%)
III + IV 95 76 (80.0%) 19 (20.0%) 0.000
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Compared with the PLV-Ctr cells, shRNA-ENO1 U251
and U87 glioma cells both showed significantly decreased
invasion (P < 0.01 for each) (Figure 5B). Similar to the sta-
bly suppressed ENO1 expression results, downregulation
of ENO1 using siRNA-ENO1 also inhibited cell migration
and invasion in U251 and U87 cells (Figure 5C, D).
ENO1 controls the expression of cell cycle and EMT
associated genes in glioma
To further study the mechanism by which ENO1 regu-
lates cell proliferation, migration and invasion, we exam-
ined protein levels of cell cycle and EMT-associated genes
in glioma U251 and U87 cells with stably suppressed
ENO1 expression. Knocking down endogenous ENO1 ex-
pression inhibited the activation of pRb (Ser 780), NF-κB




<50 vs. ≥ 50 years 0.716 1.069 0.745
Gender
Male vs. female 0.834 1.041 0.716
Histologic type
AT vs. OT vs. OAT* 0.849 1.041 0.689
ENO1 expression
Low vs. High 0.000 20.978 9.087
*AT: Astrocytic tumors; OT: Oligodendrogial tumors; OAT: Oligoastrocytic tumors.and Cyclin E1. The expression of total Rb and E2F1 were
not affected (Figure 6A). Further, we found that suppress-
ing ENO1 expression decreased the expression of Snail,
β-catenin, Vimentin, Slug and N-cadherin, while elevated
E-cadherin expression (Figure 6B).
ENO1 regulates PI3K/Akt pathway
The PI3K/Akt protein complex has been reported to
play an important role in modulating cell cycle and
EMT activities. We examined the effect of ENO1 on
PI3K/Akt pathway and found that reduced ENO1 signifi-
cantly decreased the phosphorylation of PI3K and Akt,
but not their total protein levels (Figure 6C). Treatment
of glioma U251 and U87 cells with LY294002 had a
similar effect on E-Cadherin, Cyclin D1, and p-Rb as
ENO1 knockdown (Figure 6D). These results suggested
that ENO1 is an upstream factor modulating the PI3K/
Akt pathway in glioma.
Discussion
Gliomas cells are known to have more glycolytic activ-
ities than NB tissue, especially in glioblastomas (GBM)
[15]. Robust migration of GBM cells has been previously
demonstrated under glycolytic conditions and their
pseudopodia contain increased glycolytic and decreased
mitochondrial enzymes [16]. GBM commonly exhibit
large areas of hypoxia in situ, with the potential for ac-
cumulation of intracellular metabolic acids, such as lac-
tic and citric acid [17]. ENO1 is a glycolysis enzyme
crucial for anabolic processes and energy generation
[18], and is the major enolase isoform in GBM, account-
ing for 75–90% of cellular enolase activity [19]. Silencing
of ENO2 mediated by shRNA selectively inhibits growth,
survival and the tumorigenic potential of ENO1-deleted
GBM cells, and that the enolase inhibitor phosphonoa-
cetohydroxamate is selectively toxic to ENO1-deleted
GBM cells relative to ENO1-intact GBM cells or normal
astrocytes [20]. Enolase was the most sensitive marker of
pathological change and was the only enzyme found toon analysis of overall survival duration
Multivariate analysis
% CI P HR 95% CI
-1.534 0.989 1.003 0.691-1.456
-1.514 0.177 1.303 0.887-1.915
-1.574 0.187 1.335 0.870-2.048
-48.430 0.000 26.214 10.766-63.827
Figure 2 Kaplan-Meier survival analysis of overall survival
duration in 136 glioma patients according to ENO1 protein
expression. Accumulation expression of ENO1 was unfavorable for
glioma prognosis. The log-rank test was used to calculate P values.
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low grade astrocytomas [21]. Therefore, enzymes and
other proteins that protect glycolytic activity from acid-
osis need to be identified and investigated as targets to
improve therapies of these invasive tumors.
Since the ENO1 promoter contains a hypoxia respon-
sive element, the overexpression of ENO1 is associated
with tumor development through a process known as
aerobic glycolysis or the Warburg effect [22]. The mech-
anism of the Warburg effect was uncertain until theFigure 3 Effect of shRNA to stably knock down the expression of ENO
included PLV-Ctr. (A). RT-PCR shows transcriptional levels of the ENO1 gene
expression levels in shENO1 and PLV-Ctr treatments. A representative imag
control. Bar graph shows the relative expression of protein among the gro
experiments (*P < 0.05, **P > 0.05).recent identification of upregulation of glycolytic en-
zymes by hypoxia-inducible factor. Together these find-
ings suggest that ENO1 may play a unique role in the
Warburg effect of glioma cells. Nevertheless, more de-
tailed and non-overlapping potential functions of the pro-
tein remain poorly understood. Several studies have
shown that, besides its major role in glycolysis, ENO1 is a
multifunctional protein displaying a range of distinct ac-
tivities. It is a hypoxic stress protein in endothelial cells
[23], a heat shock protein in yeast, a lens crystalline and
an autoimmune antigen [24].
Though Enolase was observed increased in the cere-
brospinal fluid of patients with low grade astrocytoma
[21], in the present study, we investigated tumor tissues.
First, we confirmed that ENO1 mRNA levels were
higher in 45 glioma samples than in 15 NB tissues. Con-
sistent with mRNA levels, ENO1 protein expression was
significantly elevated in 10 glioma samples compared to
4 NB tissues. We used immunohistochemistry to further
examine the expression level and subcellular localization
of ENO1 in glioma and NB tissues. We found that
ENO1 was mainly localized in the cytoplasm of glioma
tissues while weakly expressed in cytoplasm in NB tis-
sues. We also observed that the expression level of
ENO1 was positively correlated with tumor grading as
there was a significant difference between high and low
grade gliomas. Multivariate analyses showed that in-
creased expression of ENO1 protein was a significant1 in human glioma cell lines U251 and U87. Different treatments
with ARF used as a loading control. (B). Western blot showing protein
e of three different experiments is shown. β-actin served as a loading
ups. Data are presented as mean ± SD for three independent
Figure 4 (See legend on next page.)
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Figure 4 Stably downregulated ENO1 expression suppressed cell proliferation in vitro and tumorigenicity in vivo. (A). Effect of ENO1
knockdown on U251 and U87 cell proliferation as measured by MTT assay. Absorbance was read at 490 nm with averages from triplicate wells.
Data are presented as mean ± SD for three independent experiments. (B). Transiently reducing the expression of ENO1 by siRNA inhibited cell
proliferation in glioma U251 and U87 cells. (C). In vitro proliferative ability of glioma cells was significantly decreased in ENO1-suppressed cells
compared to PLV-Ctr cells by colony formation assay. (D). When compared with PLV-Ctr, tumorigenicity of shENO1-U25 and shENO1-U87 cells
was markedly reduced in vivo (*P < 0.05). (E). Immunohistochemical (IHC) staining of ENO1 expression in subcutaneous tumors of mice injected
with shENO1 and PLV-Ctr cells.
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data strongly imply an oncogenic role for ENO1 in gli-
oma tumorigenesis.
In previous studies, elevated expression of ENO1 was
positively associated with progression and poor progno-
sis in neuroendocrine tumors, neuroblastoma, pancreatic
cancer, prostate cancer, cholangiocarcinoma, thyroid
carcinoma, lung cancer, hepatocellular carcinoma andFigure 5 Stably inhibited ENO1 expression decreases cell migration a
ability of shENO1-U251 and shENO1-U87 cells in vitro. (B). Stably suppresse
cells. (C). Transiently downregulated ENO1 dramatically decreased the migr
ENO1 inhibited in vitro invasion of U251 and U87 cells. Data were presente
*P < 0.05, statistically significant difference.breast cancer, and suggested an involvement of ENO1
in tumor progression [25-32]. The biological functions
of ENO1 found in this study provided a mechanistic
basis for the pathological and clinical observations.
We found that stably decreased expression of ENO1
by shRNA inhibited glioma cell proliferation, migra-
tion, and invasion in vitro and decreased tumorigen-
esis in vivo compared to the PLVM-Ctr groups.nd invasion. (A). Stably downregulating ENO reduced the migration
d ENO1 reduced in vitro invasion of shENO1-U251 and shENO1-U87
ation ability of U251 and U87 cells in vitro. (D). Transiently suppressed
d were presented as mean ± SD for three independent experiments.
Figure 6 ENO1 controls the expression of cell cycle and EMT-associated genes in glioma via PI3K/Akt pathway. (A). Knocking down
endogenous ENO1 expression reduced the expression of pRb (Ser 780), NF-κB, and oncogenic cell cycle regulators including Cyclin D1 and Cyclin E1.
However, total Rb and E2F1 were not affected. (B). Suppressing ENO1 expression decreased the expression of EMT-marker genes including Snail,
β-catenin, Vimentin, Slug and N-cadherin but enhanced E-cadherin expression. (C). Reduced ENO1 expression depressed the expression of phos-PI3K,
and Akt, but not their total protein levels. (D). Western blot analyses of E-cadherin, Cyclin D1, p-Rb in glioma U251 and U87 cells after LY294002
treatment. Each experiment was repeated three times.
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complex network of Cyclin D, CDKs, Rb and Rb-related
proteins [33]. Both of these pathways are required for
hyperphosphorylation of the retinoblastoma gene prod-
uct (pRb) [34]. In this investigation, we examined key
cell growth regulators and observed that Cyclin D1, Cyc-
lin E1, pRb, and NF-κB were downregulated after stable
ENO1 knockdown in glioma U251 and U87 cells.
EMT is involved in cell migration and invasion which
are key steps in the progression of glioma [35]. The loss
of E-cadherin and overexpression of mesenchymal cell
markers such as N-cadherin, Vimentin are hallmarks of
EMT [36]. Our data indicated that knockdown of ENO1
resulted in restoration of E-cadherin expression and
suppression of Vimentin expression in glioma cells. Fur-
thermore, we observed that ENO1 downregulation also
inhibited the expression of other mesenchymal cell markers
such as Snail, N-Cadherin, β-Catenin and Slug.
PI3K/Akt is a classical signal pathway [37-39], and its
activated status induces cell growth [40,41], increases
the expression of Snail and promotes the EMT [42]. In
this study, we also observed that decreased ENO1 ex-
pression suppressed pPI3K and pAkt levels, while notaffecting total PI3K and Akt protein levels. Suppression
of PI3K in U251 and U87 glioma cells with LY294002
treatment led to the upregulation of E-cadherin while
decreasing Cyclin D1 and p-Rb. We hypothesize that
ENO1 may contribute to tumor progression via the PI3K/
Akt pathway mediating the activity of Cyclin D1, Cyclin E,
and NF-κB, which will eventually result in hyperphosphor-
ylation of Rb and downregulation of E-cadherin mediated
classical EMT.
Conclusion
In summary, ENO1 expression may have significant
value as an unfavorable progression indicator for glioma
patients. We provide compelling evidence that attenu-
ated ENO1 expression leads to suppressed cell growth,
migration and invasion progression by inactivating the
PI3K/Akt pathway in glioma cells.
Materials and methods
Cell culture and sample collection
The human glioma cell line U251,U87 were purchased from
the Chinese Academy of Sciences (Shanghai, China) and
grown in Dulbecco’s modified Eagle’s medium (DMEM)
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serum (ExCell, Shanghai, China). All cell lines were cul-
tured at 37°C in a humidified atmosphere of 5% CO2. A
total of 136 paraffin-embedded glioma and 15 NB tissues
samples were obtained from the Nanfang Hospital of
Southern Medical University, Guangzhou, China. These
cases were from 88 males and 48 females with age ranging
from 11 to 68 years (median, 41.7 years). For the use
of these clinical materials for research purposes, prior
consent from patients and approval from the Ethics
Committees of Nanfang Hospital were obtained. All speci-
mens had confirmed pathological diagnosis and were
classified according to the World Health Organization
(WHO) criteria.
RNA isolation, reverse transcription, and qRT-PCR
RNA was extracted from the U87 and U251 cell lines, gli-
oma tissues and NB tissues using Trizol (Takara, Shiga,
Japan). For ENO1, RNA was transcribed into cDNA and
amplified with specific sense: 5′- GCCGGCTTTACG
TTCACCTC-3′, antisense primer: 5′- GTTGAAGCACC
ACTGGGCAC-3′. ARF gene was used as an internal con-
trol using the sense primer 5′-ATCTGTTTCACAGTC
TGGGACG-3′ and antisense primer 5′-CCTGCTTGTT
GGCAAATACC-3′. The assays were performed in ac-
cordance with manufacturer’s instructions (Takara, Shiga,
Japan). Cycling conditions were 95°C for 10 min to acti-
vate DNA polymerase, followed by 45 cycles of 95°C
for 15 s, 55°C for 15 s, and 72°C for 10s. Specificity
of amplification products was confirmed by melting
curve analysis. PCR reactions for each gene were re-
peated three times. Independent experiments were done
in triplicate.
Immunohistochemistry
Paraffin sections (4 μm) from samples were deparaffi-
nized in 100% xylene and re-hydrated in descending
ethanol series and water according to standard proto-
cols. Heat-induced antigen retrieval was performed in
10 mM citrate buffer for 2 min at 100°C. Endogenous
peroxidase activity and non-specific antigens were
blocked with peroxidase blocking reagent containing 3%
hydrogen peroxide and serum, followed by incubation
with rabbit anti-human ENO1 antibody (1: 150) (48 kDa,
Proteintech, USA) overnight at 4°C. After washing, the
sections were incubated with biotin-labeled rabbit anti-
goat antibody for 10 min at room temperature, and subse-
quently were incubated with streptavidin-conjugated
horseradish peroxidase (HRP) (Maixin, Fuzhou, China).
The peroxidase reaction was developed using 3,3-diami-
nobenzidine (DAB) chromogen solution in DAB buffer
substrate. Sections were visualized with DAB and counter-
stained with hematoxylin, mounted in neutral gum, and
analyzed using a bright field microscope.Evaluation of staining
The immunohistochemically stained tissue sections were
reviewed and scored separately by two pathologists
blinded to the clinical parameters. Expression of ENO1
in the nucleus and in the cytoplasm was independently
evaluated. For cytoplasmic staining, the score was evalu-
ated according to the sum of cytoplasm staining inten-
sity and the percentage of positive staining areas of cells.
The staining intensity was scored as previously described
(0–3) [43,44] and the percentage of positive staining
areas of cells was defined as a scale of 0–3 (0: <10%, 1:
10-25%, 2: 26-75%, and 3: >76%). For nuclear staining,
the staining score was defined based on the sum of nu-
clear staining intensity and the number of positive nu-
clear staining. Nuclear staining intensity score was
consistent with cytoplasm. The positive nuclear staining
scores were defined as follows: 0: <20%, 1: 20-49%, 2:
50-79%, and 3: >80%. The sum of the cytoplasm and nu-
clear staining scores were used as the final staining score
for ENO1 (0–12). For statistical analysis, a final staining
score of 0–4 and 5–6 in cytoplasm or 0–3 and 4–6 in
nucleus was considered to be low or high expression,
respectively.
Western blot analysis
Western blot was carried out according as described
[45] with rabbit polyclonal anti-ENO1 antibody (1:1000;
Proteintech, USA), anti-NF-κB, Cyclin D1, Cyclin E1 and
E2F1 antibody (1:400; Santa Cruz Biotechnology, Santa
Cruz, USA), anti-Rb, pRb (Ser,780), Akt, pAkt (Ser473),
PI3K, pPI3K (Tyr458), Snail, Slug, β-catenin, E-Cadherin,
N-Cadherin and Vimentin antibody (1:1000; Cell Signaling
Technology, Danvers, USA). An HRP-conjugated anti-
rabbit IgG antibody was used as the secondary anti-
body (Zhongshan, Beijing, China). Signals were detected
using enhanced chemiluminescence reagents (Pierce,
Rockford, IL).
Establishment of glioma cell line with stable expression
of ENO1 short hairpin RNA
The preparation of lentiviruses expressing human ENO1
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expression system [46]. U87 and U251 cells were infected
with lentiviral particles containing specific or negative
control vectors, and polyclonal cells with GFP signals
were selected for further experiments using FACS flow
cytometry. Total RNA of these cell clones was isolated,
and levels of ENO1 mRNA were measured using real-
time PCR analysis.
Transient transfection with siRNAs
Small-interfering RNA (siRNA) for ENO1 was designed
and synthesized by Guangzhou RiboBio (RiboBio Inc,
China). Three siRNAs targeting on ENO1 gene were de-
signed and synthesised, the most effective siRNA (siENOA)
identified by Real Time-PCR was applied for the further
experiments. The sequence of siENO1 is: sense: 5′-GCA
UUGGAGCAGAGGUUUAdTdT-3′; anti-sense: 3′-dTdT
CGUAACCUCGUCUCCAAAU-5′. The sequence of si-
negative control (si-Ctr) was also designed by RiboBio
(RiboBio Inc., China). Twenty-four hours prior to transfec-
tion, glioma cells U87 and U251 were plated onto a 6-well
plate or a 96-well plate (Nest Biotech, China) at 30–50%
confluence. They were then transfected into cells using
TurboFect TM siRNA Transfection Reagent (Fermentas,
Vilnius, Lithuania) according to the manufacturer’s proto-
col. Cells were collected after 48–72 hr for further
experiments.
Cell viability and proliferation assay
Cell proliferation was analyzed using MTT assay. Cells
were seeded in 96-well plates at a density of 700 cells/
well. The cells were incubated for 1, 2 or 3 days. Twenty
microliters of MTT (5 mg/ml) (Sigma, St. Louis, MO)
was added to each well and incubated for 4 hr. At the end
of incubation, supernatants were removed, and 150 μl of
DMSO (dimethyl sulfoxide) (Sigma, St. Louis, MO) was
added to each well. The absorbance value (OD) of each
well was measured at 490 nm. For each experimental con-
dition, eight wells were used. Experiments were performed
in triplicate.
Cell migration and invasion assays
In vitro cell migration and invasion assays were exam-
ined according to our previous study [47]. For the cell
migration assay, 1 × 104 cells in 100 μl DMEM medium
without FCS were seeded on a fibronectin coated poly-
carbonate membrane insert in a Transwell apparatus
(Costar, MA). In the lower chamber, 600 μl DMEM with
10% FCS was added as chemoattractant. After the cells
were incubated for 6 hr at 37°C in a 5% CO2 atmos-
phere, the insert was washed with PBS, and cells on the
top surface of the insert were removed with a cotton
swab. Cells adhering to the lower surface were fixed with
methanol, stained with Giemsa solution and countedunder a microscope in five predetermined fields (200×).
All assays were independently repeated at least three
times. For the cell invasion assay, the procedure was
similar to the cell migration assay, except that the Trans-
well membranes were precoated with 24 μg/μl Matrigel
(R&D Systems, USA) and the cells were incubated for
6 hr at 37°C in a 5% CO2 atmosphere. Cells adhering to
the lower surface were counted the same way as the cell
migration assay.
Colony formation assay
Cells were plated in 6-well culture plates at 100 cells/
well. Each cell group had 2 wells. After incubation for
12 days at 37°C, cells were washed twice with PBS and
stained with Giemsa solution. The number of colonies
containing >50 cells was counted under a microscope.
The colony formation efficiency was calculated as (num-
ber of colonies/number of cells inoculated) × 100%.
In vivo tumorigenesis in nude mice
A total of 1 × 106 logarithmically growing U251 cells
transfected with pLVTHM-GFP -ENO1 and the control
pLVTHM-GFP vector (N = 6 per group) in 0.1 ml DMEM
medium were subcutaneously injected into the left-right
symmetric flank of 4-6-week-old male BALB/c nu/nu
mice. The mice were maintained in a barrier facility on
HEPA-filtered racks. The animals were fed an autoclaved
laboratory rodent diet. All animal studies were conducted
in accordance with the principles and procedures outlined
in the National Institutes of Health Guide for the Care
and Use of Animals under assurance number A3873-1.
After 18 days, the mice were sacrificed respectively and
tumor tissues excised and weighed.
Statistical analysis
All quantified data represented an average of at least
triplicate samples. SPSS 13.0 and Graph Pad Prism 4.0
software were used for statistical analysis. Data are pre-
sented as mean ± SD. One-way ANOVA or two-tailed
Student’s t-test was used for comparisons between
groups. Chi-square test or Fischer’s were used to identify
differences between categorical variables. Survival ana-
lysis was performed using Kaplan-Meier method. Multi-
variate Cox proportional hazards method was used for
analyzing the relationship between the variables and pa-
tient’s survival time. Differences were considered statisti-
cally significant when P < 0.05.
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